A Phase 1 interventional study of Naloxone in Hypogonadotropic Hypogonadism and Low Testosterone, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Stephanie B. Seminara, MD · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.
Among the 185 studies in Hypogonadism with a site in United States, this one is the 109th largest by enrollment of the 154 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 in phase 1, and was the 169th registered.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
Browse Hypogonadism studies →12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:
Stephanie B. Seminara, MD · Sites in United States
Ages 18–45 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
Halozyme Therapeutics · Sites in United States
Ages 12–17 · Men only
Bradley Nindl · Sites in United States
Ages 18–40 · Healthy volunteers
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 62 · Phase 3 31 · Phase 4 27
First in 1989; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Median enrollment 45 across the 154 interventional studies, 70 across the 27 observational. Of the 154 that completed or were terminated, 84 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 185 have an industry lead sponsor. The 10 most frequent:
Stephanie B. Seminara, MD is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Stephanie B. Seminara, MD has 6 studies filed under Hypogonadism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypogonadism with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04301765Seattle Institute for Biomedical and Clinical ResearchImproving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency | 2026-11 |
| NCT06720597University of California, IrvineEndoPAT Device for Endothelial Dysfunction in ED | 2027-01 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT06455969Bradley NindlAdaptions and Resiliency to Multi-Stressor OpeRations | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 185 studies in Hypogonadism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).
Assignment: Each study subject will serve as their own control.
Delivery of Interventions:
During the study, the subjects will undergo the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one period of frequent blood sampling with IV administration of naloxone (one bolus)
Drug: Naloxone
One bolus of naloxone
Average Change in Mean Luteinizing Hormone (LH) Value
Change in mean LH before vs. after naloxone bolus
Time frame: Before and after treatment, a 3 hour period on a single study day
Boston area. 23 participants were consented and screened for eligibility between 6/2025 and 8/2025.
| Milestone | Naloxone |
|---|---|
| Started | 9 |
| Completed | 9 |
| Not completed | 0 |
Change in mean LH before vs. after naloxone bolus
| IU/L | Naloxone |
|---|---|
| Average Change in Mean Luteinizing Hormone (LH) Value | 1.571 ± 2.714 |
Collected over From time of study consent until removal from study participation (approximately 5 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naloxone | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Age, Categorical(Participants) | Naloxone |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 5 |
| >=65 years | 4 |
| Sex: Female, Male(Participants) | Naloxone |
|---|---|
| Female | 0 |
| Male | 9 |
| Race (NIH/OMB)(Participants) | Naloxone |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Naloxone |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2025 to primary completion in Sep 2025, 3 months.
Results were first posted in May 2026, 7 months after primary completion.
Of 13 phase 1 interventional studies under Hypogonadism, half reached primary completion within 32 months of starting (the median); a quarter within 18 and three quarters within 57. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naloxone
Stephanie B. Seminara, MD